Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315905 | 0.76 | — | — | |
| SCHEMBL4533845 | 0.76 | — | — | |
| SCHEMBL25316899 | 0.76 | — | — | |
| SCHEMBL8291836 | 0.75 | L3MBTL1 (0.60) | L3MBTL1 | |
| SCHEMBL15289240 | 0.75 | L3MBTL1 (0.60) | L3MBTL1 | |
| SCHEMBL24693273 | 0.75 | L3MBTL1 (0.60) | L3MBTL1 | |
| SCHEMBL13722786 | 0.75 | L3MBTL1 (0.60) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29539199 | 0.73 | L3MBTL1 (0.55) | L3MBTL1 | |
| SCHEMBL20584503 | 0.72 | — | — | |
| SCHEMBL25152032 | 0.72 | L3MBTL1 (0.56) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021057970-A1 | RET INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-2471773-A1 | Piperidinyl derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| CN-101842375-A | Process for preparing TEDA derivatives | BASF SE | 2010-09-22 | — | — | CN | disclosed |
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2197882-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | Basf Se (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030649-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2009-03-12 | — | — | WO | disclosed |
| US-6147185-A | POLYMERIZATION CATALYST SELECTIVE TO BALANCE POLYMERIZATION GELATION AND FOAMING BY WATER USED AS BLOWING AGENT | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | TES, TRRAP, NAAA | L3MBTL1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.